* receipt of any covid-19 vaccine during this study and follow-up period * prior positive sars-cov2 test * hepatitis b virus (hbv), hepatitis c virus (hcv), or uncontrolled human immunodeficiency virus (hiv) infection * use of any nasally administered drug mild-moderate covid patients inclusion criteria: * is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age * agrees to use contraception through 3 months after the last dose of igm-6268 * agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol. * signs and symptoms of mild to moderate covid-19 but not requiring hospitalization * has a laboratory-confirmed sars-cov-2 infection as determined by fda-authorized antigen or naat diagnostic assay during the period of 72 hours prior to enrollment.

* receipt of any covid-19 vaccine during this study and follow-up period * prior positive sars-cov2 test * hepatitis b virus (hbv), hepatitis c virus (hcv), or uncontrolled human immunodeficiency virus (hiv) infection * use of any nasally administered drug mild-moderate covid patients inclusion criteria: * is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age * agrees to use contraception through 3 months after the last dose of igm-6268 * agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol. * signs and symptoms of mild to moderate covid-19 but not requiring hospitalization * has a laboratory-confirmed sars-cov-2 infection as determined by fda-authorized antigen or naat diagnostic assay during the period of 72 hours prior to enrollment.

receipt of any covid-19 vaccine during this study and follow-up period prior positive sars-cov2 test hepatitis b virus (hbv), hepatitis c virus (hcv), or uncontrolled human immunodeficiency virus (hiv) infection use of any nasally administered drug mild-moderate covid patients inclusion criteria: is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age agrees to use contraception through 3 months after the last dose of igm-6268 agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol. signs and symptoms of mild to moderate covid-19 but not requiring hospitalization has a laboratory-confirmed sars-cov-2 infection as determined by fda-authorized antigen or naat diagnostic assay during the period of 72 hours prior to enrollment.

receipt of any covid-19 vaccine during this study and follow-up period prior positive sars-cov2 test hepatitis b virus (hbv), hepatitis c virus (hcv), or uncontrolled human immunodeficiency virus (hiv) infection use of any nasally administered drug mild-moderate covid patients inclusion criteria: is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age agrees to use contraception through 3 months after the last dose of igm-6268 agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol. signs and symptoms of mild to moderate covid-19 but not requiring hospitalization has a laboratory-confirmed sars-cov-2 infection as determined by fda-authorized antigen or naat diagnostic assay during the period of 72 hours prior to enrollment.